心血管

订阅

MedSci主页 / 所有栏目 / 心血管

JAMA：氯沙坦不会增加心衰患者死亡风险

2012-04-25 陈智 中国医学论坛报

氯沙坦心力衰竭
关注

　　丹麦的一项以国家登记注册为基础的队列研究显示，对于心力衰竭患者，同坎地沙坦相比，氯沙坦和死亡风险增加之间无相关性。尽管低剂量的氯沙坦与死亡增加存在相关，同最大剂量的坎地沙坦相比，高剂量氯沙坦并不会增加死亡发生。文献4月11日在线发表于《美国医学会杂志》（JAMA）。    

　　丹麦的一项以国家登记注册为基础的队列研究显示，对于心力衰竭患者，同坎地沙坦相比，氯沙坦和死亡风险增加之间无相关性。尽管低剂量的氯沙坦与死亡增加存在相关，同最大剂量的坎地沙坦相比，高剂量氯沙坦并不会增加死亡发生。文献4月11日在线发表于《美国医学会杂志》（JAMA）。



    

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1700925, encodeId=8bc41e0092592, content=<a href='/topic/show?id=44d4641040e' target=_blank style='color:#2F92EE;'>#氯沙坦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64104, encryptionId=44d4641040e, topicName=氯沙坦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8eef30296447, createdName=listen328, createdTime=Mon Dec 31 06:16:00 CST 2012, time=2012-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983391, encodeId=dcf71983391f2, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Dec 31 14:16:00 CST 2012, time=2012-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255403, encodeId=27f4125540356, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Fri Apr 27 02:16:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373236, encodeId=074813e32365b, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Fri Apr 27 02:16:00 CST 2012, time=2012-04-27, status=1, ipAttribution=)]
    2012-12-31 listen328

    #氯沙坦#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1700925, encodeId=8bc41e0092592, content=<a href='/topic/show?id=44d4641040e' target=_blank style='color:#2F92EE;'>#氯沙坦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64104, encryptionId=44d4641040e, topicName=氯沙坦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8eef30296447, createdName=listen328, createdTime=Mon Dec 31 06:16:00 CST 2012, time=2012-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983391, encodeId=dcf71983391f2, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Dec 31 14:16:00 CST 2012, time=2012-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255403, encodeId=27f4125540356, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Fri Apr 27 02:16:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373236, encodeId=074813e32365b, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Fri Apr 27 02:16:00 CST 2012, time=2012-04-27, status=1, ipAttribution=)]
    2012-12-31 sunylz

    #患者死亡#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1700925, encodeId=8bc41e0092592, content=<a href='/topic/show?id=44d4641040e' target=_blank style='color:#2F92EE;'>#氯沙坦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64104, encryptionId=44d4641040e, topicName=氯沙坦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8eef30296447, createdName=listen328, createdTime=Mon Dec 31 06:16:00 CST 2012, time=2012-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983391, encodeId=dcf71983391f2, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Dec 31 14:16:00 CST 2012, time=2012-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255403, encodeId=27f4125540356, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Fri Apr 27 02:16:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373236, encodeId=074813e32365b, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Fri Apr 27 02:16:00 CST 2012, time=2012-04-27, status=1, ipAttribution=)]
    2012-04-27 quxin068

    #死亡风险#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1700925, encodeId=8bc41e0092592, content=<a href='/topic/show?id=44d4641040e' target=_blank style='color:#2F92EE;'>#氯沙坦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64104, encryptionId=44d4641040e, topicName=氯沙坦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8eef30296447, createdName=listen328, createdTime=Mon Dec 31 06:16:00 CST 2012, time=2012-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983391, encodeId=dcf71983391f2, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Dec 31 14:16:00 CST 2012, time=2012-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255403, encodeId=27f4125540356, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Fri Apr 27 02:16:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373236, encodeId=074813e32365b, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Fri Apr 27 02:16:00 CST 2012, time=2012-04-27, status=1, ipAttribution=)]
    2012-04-27 yuanming7

    #心衰患者#

    0

相关资讯

JAMA：大剂量氯沙坦与心衰死亡增加无关

　　据4月11日刊《美国医学会杂志》上的一项研究披露，尽管观察性研究提示，氯沙坦与其他同类药物[血管紧张素Ⅱ受体阻滞剂（ARB）]相比可能与心衰患者死亡风险升高有关，但一则包括了近6500名患者的分析发现，总的来说，与ARB坎地沙坦的使用相比，氯沙坦的使用与全因死亡或心血管性死亡的增加无关。 　　丹麦哥本哈根Statens Serum研究所的Henrik Svanstrom,